Whalesbook
Patent Expiry Sparks Generic Surge
India's semaglutide patent expired on March 20, unleashing a wave of domestic generic versions of Ozempic and Wegovy. Local drugmakers are aggressively pricing their offerings, cutting costs by 50% to 80% compared to the original brands.
Sales Data Shows Market Shift
Industry tracker Pharmarack Technologies reported a significant downturn for Tirzepatide (Mounjaro) sales in March, dropping to ₹114 crore from ₹135 crore in February—a nearly 16% decrease. Meanwhile, semaglutide sales rose to ₹59 crore in March from ₹48 crore the prior month. Total GLP-1 agonist sales in the segment fell to ₹180 crore in March, down from ₹191 crore in February. Sales for comparable drugs like Dulaglutide and Liraglutide remained steady.
Domestic Players Vie for Market Share
Around 13 companies have already launched 26 generic semaglutide versions, with more on the way. Novo Nordisk led semaglutide sales in March, taking ₹45 crore with Ozempic, Wegovy, and Rybelsus. However, domestic firms are rapidly gaining ground: Torrent Pharma recorded ₹4.7 crore, Dr. Reddy's Laboratories ₹1.9 crore, Zydus Lifesciences ₹1.4 crore, Lupin ₹1.4 crore, and Sun Pharma ₹0.90 crore.
Sheetal Sapale, Vice-President, Commercial at Pharmarack, called it a "classic 'gold rush phase'," noting that while many are participating, value capture will be limited to a few key players.
Regulatory Oversight and Future Outlook
Authorities have advised that these drugs should only be prescribed to eligible patients, but concerns about misuse continue. Experts suggest that while regulations may shape the market, they are unlikely to halt the initial rapid growth of generic launches. More aggressive introductions are expected, potentially mirroring an 'exponential growth phenomenon' seen by April 2026. Innovator companies like Novo Nordisk are focusing on 'innovator-driven efficacy and increased share of voice' through partnerships, with pricing expected to be a key factor going forward.